Treatment of Crigler-Najjar Syndrome with Severe Unconjugated Hyperbilirubinemia and No Significant Response to Phenobarbital
This protocol covers the management of Crigler-Najjar syndrome Type I (CNS1) — the severe form defined by a complete absence of UGT1A1 enzymatic activity. With no capacity for bilirubin glucuronidation, patients develop severe unconjugated hyperbilirubinemia that does not respond to phenobarbital and carries a high risk of kernicterus without immediate and sustained intervention.
Clinical Scenario
Complete loss of UGT1A1 activity — arising from deletions, insertions, missense mutations, or premature stop codons — results in severe unconjugated hyperbilirubinemia from birth. A phenobarbital trial produces no significant reduction in serum bilirubin, confirming Type I disease. Without prompt treatment, the persistently elevated bilirubin poses a direct risk of kernicterus and irreversible neurologic injury.
Treatment Approach
Phototherapy is the cornerstone of management, initiated as early as possible after birth and sustained daily — the full regimen, including adjunctive measures to further support bilirubin clearance, is available in the complete protocol.
Clinical Goal
Maintain total serum bilirubin below 30 mg/dL and keep the bilirubin/albumin ratio below 1.0 mol/mol — the thresholds above which neurotoxic risk is considered significant.
References
DOI: 10.3390/ijms252011006
- Type I disease (CNS1) is characterized by severe jaundice and a high risk of neurologic sequelae (kernicterus), resulting from the complete absence of enzymatic activity; type II disease (CNS2) is a milder form with decreased enzyme activity, lower serum bilirubin levels, and little to no risk of kernicterus.
- In CNS1, there is a complete loss of UGT1A1 activity due to deletions, insertions, missense mutations, or premature stop codons, resulting in severe unconjugated hyperbilirubinemia.
- Patients with CNS1 do not respond to phenobarbital and require long-term phototherapy to keep serum bilirubin levels within safe limits.
- In contrast, CNS1 patients require immediate and sustained phototherapy to reduce the risk of kernicterus.
- TSB ≥ 30 mg/dL and a B/A ratio ≥ 1.0 mol/mol are considered absolute thresholds for neurotoxicity.